Clinical Development Programs

The Astellas partnership includes a treatment for hypercholesterolemia (evolocumab), a treatment for osteoporosis (romosozumab) and a treatment for oncology (blinatumomab).

Co-developed Pipeline Medicines between Amgen Astellas BioPharma and Astellas Pharma

General Name
(Development Code)		 Lead Indication Mode of Action Development Stage
Overseas Japan
Evolocumab (AMG 145) Hypercholesterolemia Anti-PCSK-9 mAb Launch Launch
Romosozumab (AMG 785)1 Osteoporosis Anti-Sclerostin mAb Launch Launch
Blinatumomab (AMG 103) Acute Lymphoblastic
Leukemia (ALL)		 Anti-CD19 BiTE® Launch Launch

As of February, 2020

1  Developed in collaboration with UCB

Pipeline Medicines by Amgen Astellas BioPharma

General Name
(Development Code)		 Lead Indication Mode of Action Development Stage
Overseas Japan
Talimogene Laherparepvec(AMG 678) Malignant Melanoma Oncolytic Virus Launch Phase 1
Erenumab(AMG 334) Migraine prevention Anti-CGRP Receptor
mAb		 Launch Phase 3
Omecamtiv Mecarbil
(AMG 423)2		 Chronic heart failure Cardiac myosin
activator 		Phase 3 Phase 3

As of May, 2019

2  Omecamtiv Mecarbil is being developed under a collaboration between Amgen Inc. and Cytokinetics, Inc., with funding and strategic support from LES LABORAT0IRES SERVIER AND INSTITUT DE RECHERCHES INTERNATIONALES SERVIER